The Russian startup "Ligand Pro", created by Skoltech specialists, has introduced an artificial intelligence platform for the early stages of drug development. The system helps generate and optimize molecules, model their interaction with proteins, and check the patent landscape.
The developers have integrated several tools into one cycle. Researchers do not have to transfer results between different programs: the platform maintains the logic of work from hypothesis formulation to the selection of promising compounds for further synthesis and testing.
We make advanced AI tools accessible to pharmaceutical companies and research teams.
The system is primarily designed for the initial stage of searching for drug candidates. It can help scientists more quickly select molecules worth further investigation, but it does not replace laboratory and clinical trials.
Currently, the platform is undergoing closed testing with the participation of pharmaceutical companies and research teams. Developers also use the ability to perform a large number of calculations and simultaneously analyze the patent landscape.